This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Combination therapy with creatine monohydrate, CoQ10, and lipoic acid was shown to improve "surrogate markers of cellular energy dysfunction" in some patients with different forms of mitochondrial cytopathies, including MELAS patients. The administration of L-arginine during acute stroke-like episodes has been shown to "[decrease] severity of stroke-like symptoms in MELAS, [enhance] dynamics of the microcirculation, and also [reduce] tissue injury from ischemia." High-dose taurine supplementation was used in a phase III clinical trial in which therapy was shown to "reduce the annual relapse rate of stroke-like episodes from 2.22 to 0.72". Taurine supplementation promotes resurgence of normal metabolic activity through the modulation of calcium homeostasis in dysfunctional mitochondria.
=== Heavy metals present in the clinker === The presence of heavy metals in the clinker arises both from the natural raw materials and from the use of recycled by-products or alternative fuels. The high pH prevailing in the cement porewater (12.5 < pH < 13.5) limits the mobility of many heavy metals by decreasing their solubility and increasing their sorption onto the cement mineral phases. Nickel, zinc and lead are commonly found in cement in non-negligible concentrations. Chromium may also directly arise as natural impurity from the raw materials or as secondary contamination from the abrasion of hard chromium steel alloys used in the ball mills when the clinker is ground. As chromate (CrO42−) is toxic and may cause severe skin allergies at trace concentration, it is sometimes reduced into trivalent Cr(III) by addition of ferrous sulfate (FeSO4).
==== Commercialization ==== The company announced in November 2021 that it aims to achieve mass-manufacturing in 2024 of its silicon batteries, having pouch-cell samples produced by its manufacturing partner EVE Energy sent to be tested by global car makers. The company announced in 2023 that its batteries will be commercially available in VinFast vehicles in 2025. The CEO said that the company does not plan to become a battery manufacturer or supplier, but instead plans to license its technology to major manufacturers or lease dedicated manufacturing capacity from existing suppliers, saying its silicon batteries can be manufactured using existing factories and manufacturing processes. StoreDot demonstrated its batteries in a prototype Polestar 5 sedan in 2024, however the 2025 model was not set to debut with StoreDot batteries but with batteries developed and manufactured by SK On. StoreDot batteries were still in the testing phase in October 2024 and they had not been incorporated into any upcoming vehicle platforms. StoreDot stated in 2026 it needs two more years of development in order to commercialize its product.
=== Multimodal methods === ImmunoStruct is a multimodal deep learning approach to immunogenicity prediction that fuses information from peptide–MHC sequence, structure, and biochemical properties. Rather than treating protein sequences as text alone, it combines complementary representations of the data to model interactions relevant to antigen presentation and T cell recognition. ImmunoStruct has demonstrated strong predictive performances on infectious disease epitopes (IEDB dataset) and human cancer neoepitopes (CEDAR dataset), and is generalizable to SARS-CoV-2 epitopes and cancer survival prediction. Its multimodal attention mechanism allows the model to differentially weight sequence, structural, and biochemical features for individual peptides, enabling analysis of structural determinants and peptide–MHC interactions associated with immunogenicity.
Sources: en.wikipedia.org
There is no high-quality evidence showing that tea consumption has health effects, other than possibly increasing alertness caused by caffeine in the leaves. There is insufficient evidence that tea polyphenols have any effect on health or lowering disease risk. Black and green teas contain no essential nutrients in significant amounts, with the exception of the dietary mineral manganese, at 0.5 mg per cup or 26% of the Reference Daily Intake. Fluoride is sometimes present in tea; certain types of "brick tea", made from old leaves and stems, have the highest levels, enough to pose a health risk if too much tea is drunk, which has been attributed to high levels of fluoride in soils, acidic soils, and long brewing.
=== Synthetic forms === Some synthetic compounds also have vitamin K activity in humans. One synthetic drug with vitamin K activity still used in developed countries (the UK) is menadiol sodium diphosphate. Unlike natural vitamin K, it is water-soluble and can be absorbed without the help of bile salts.
Galanin-like peptide (GALP) is a neuropeptide present in humans and other mammals. It is a 60-amino acid polypeptide produced in the arcuate nucleus of the hypothalamus and the posterior pituitary gland. It is involved in the regulation of appetite and may also have other roles such as in inflammation, sex behavior, and stress. Findings additionally suggest that GALP could play a function in energy metabolism due to its ability to maintain continual activation of the sympathetic nervous system (SNS) via thermogenesis, which refers to the production of heat within living organisms. In addition, the administration of GALP directly into the brain leads to a reduction in the secretion of thyroid-stimulating hormone (TSH), which indicates the involvement of GALP in the neuroendocrine regulation of the hypothalamic-pituitary-thyroid (HPT) axis, and further adding to the evidence of the role of GALP in energy homeostasis.
The Mediterranean coast was well known to the Carthaginians. Their close relations with Phoenician-Punic settlements and shared cultural ties likely gave them considerable political and economic influence there from the 6th or 5th century BC, alongside the establishment of unequal treaties with Iberian city-states. After Carthage's defeat by Rome in the First Punic War, it sought new western territories, culminating in the Barcid conquest of the Iberian Peninsula in 237 BC. The Romans invaded the Iberian Peninsula in 218 BC and expelled the Carthaginians after the Battle of Ilipa in 206 BC. Within 200 years, mainland Portugal had been annexed by the Romans despite resistance from local tribes such as the Lusitanians under the leadership of Viriathus and other leaders. In 409, with the decline of the Western Roman Empire, the Iberian Peninsula was invaded by Germanic tribes. Western Iberia was integrated into the Suebian Kingdom, with its capital in or near Braga. The Visigoths defeated the Suebi in 585 and ruled the peninsula until the early 8th century. In 711, the Iberian Peninsula was invaded from the south by the Umayyad Caliphate, which expanded rapidly. By 716, present-day mainland Portugal was part of the Muslim Iberian territories known as al-Andalus.
==== Suprageneric subdivisions ==== Due to the diversity of the originally broadly defined Liliaceae s.l., many attempts have been made to form suprageneric classifications, e.g. subfamilies and tribes. Classifications published since the use of molecular methods in phylogenetics have taken a narrower view of the Liliaceae (Liliaceae s.s.). The Angiosperm Phylogeny Website (APweb) recognizes three subfamilies, one of which is divided into two tribes.
Sources: en.wikipedia.org
Efforts are ongoing to find medications that either return the ability to make dystrophin or utrophin. Other efforts include trying to block the entry of calcium ions into muscle cells. Recent reports have revealed gut microbiome dysbiosis influencing muscle pathophysiology through the immune system of dystrophin‐deficient mice and managing of gut dysbiosis with sodium butyrate supplementation (NaB) in mdx mice is reported with rescuing muscle strength and halting inflammation. In human clinical studies, epigenetic manipulation as a potential mechanism through gut microbiome balancing yielding clinically encouraging outcome have been reported, warranting further in-depth evaluation in this direction.
As opposed to the member states, the relation of EU law and international law is debated, particularly relating to the European Convention on Human Rights and the United Nations. All individual EU member states are party to both organisations through international treaties. The Treaty on European Union article 6(2) required the EU to accede to the ECHR, but would "not affect the Union's competences as defined in the Treaties". This was thought necessary before the Treaty of Lisbon to ensure that the EU gave adequate protection to human rights, overseen by the external European Court of Human Rights in Strasbourg. However, in Opinion 2/13, after a request by the commission to review their plan to accede, the Court of Justice (in Luxembourg) produced five main reasons why it felt that the accession agreement as it stood was incompatible with the treaties. In summary, these were it (1) undermined the CJEU's autonomy (2) allowed for a parallel dispute resolution mechanism among member states, when the treaties said the CJEU should be the sole arbiter (3) the "co-respondent" system, allowing the EU and member states to be sued together, allowed the ECtHR to illegitimately interpret EU law and allocate responsibility between the EU and member states, (4) did not allow the Court of Justice to decide if an issue of law was already dealt with, before the ECHR heard a case, and (5) the ECtHR was illegitimately being given power of judicial review over Common Foreign and Security Policy.
== Later life and FOP progression == Unaware of the consequences of surgery on an FOP patient, the physician admitted Eastlack for hip surgery in 1941 which caused further physical restriction. Over time Eastlack became more and more immobilized as more joints became fused and newly formed sheets or strings of bone calcified his limbs. In 1944, he was readmitted for a study which confirmed that the calcified smooth muscles, tendons, and ligaments had indeed become mature bone. The ossification along his vertebrae and other anatomical parts that Eastlack would suffer in the next 29 years ultimately fused him into a permanently bowed position. Eastlack's case of FOP progressed at a more rapid rate due to the number of intrusive surgeries he underwent. In 1948, at the age of 15, his jaw had become fused so he could no longer eat solid food and had to speak through clenched teeth. At a young age, he faced difficulty sitting down, as well. His hips were one of the first anatomical parts to become immobilized due to heterotopic ossification. Soon, bone formed across his upper arms and extended onto his sternum, tying his arms to his breast. Sheets of bone spread along his back and ribbons of bone extended from there to his skull, inhibiting proper head movement. The new bone growths throughout the years also caused juts of bone to form on his pelvis and thighs, and it caused both of his feet to become clubbed. One year he accidentally bumped his buttocks into a radiator, and this resulted in a bruise wherein the smooth tissue was destroyed and gave way to newly formed bone.
== Definition == Pressure is the amount of force applied perpendicular to the surface of an object per unit area. The symbol for it is p or P. The IUPAC recommendation for pressure is a lower-case p. However, upper-case P is widely used. The usage of P versus p depends upon the field in which one is working, on the nearby presence of other symbols for quantities such as power and momentum, and on writing style.
== Diagnosis == Weissenbacher-Zweymüller syndrome is diagnosed upon a thorough clinical evaluation, detailed patient history, identification of characteristic symptom and a variety of specialized tests which includes x-rays.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.